Iron Hydroxide Polymaltose + Folic acid + Zinc Sulfate Monohydrate

Iron Hydroxide Polymaltose + Folic acid + Zinc Sulfate Monohydrate Uses, Dosage, Side Effects, Food Interaction and all others data.

Each film-coated tablet contains- Iron (III) Hydroxide Polymaltose Complex INN 188 mg equivalent to 47 mg elemental Iron Folic Acid BP 0.50 mg Zinc Sulfate Monohydrate USP 61.80 mg equivalent to 22.50 mg elemental Zinc.

Trade Name Iron Hydroxide Polymaltose + Folic acid + Zinc Sulfate Monohydrate
Generic Iron Hydroxide Polymaltose + Folic acid + Zinc Sulfate Monohydrate
Type
Therapeutic Class Iron, Vitamin & Mineral Combined preparation
Manufacturer
Available Country Bangladesh
Last Updated: September 24, 2024 at 5:38 am
Iron Hydroxide Polymaltose + Folic acid + Zinc Sulfate Monohydrate
Iron Hydroxide Polymaltose + Folic acid + Zinc Sulfate Monohydrate

Uses

This is used for the prevention and treatment of Iron, Folic Acid and Zinc deficiencies.

Iron Hydroxide Polymaltose + Folic acid + Zinc Sulfate Monohydrate is also used to associated treatment for these conditions: Anaemia folate deficiency, Folate deficiency, Iron Deficiency (ID), Iron Deficiency Anemia (IDA), Latent Iron Deficiency, Neural Tube Defects (NTDs), Vitamin Deficiency, Methotrexate toxicity, Nutritional supplementation

How Iron Hydroxide Polymaltose + Folic acid + Zinc Sulfate Monohydrate works

Folic acid, as it is biochemically inactive, is converted to tetrahydrofolic acid and methyltetrahydrofolate by dihydrofolate reductase (DHFR). These folic acid congeners are transported across cells by receptor-mediated endocytosis where they are needed to maintain normal erythropoiesis, synthesize purine and thymidylate nucleic acids, interconvert amino acids, methylate tRNA, and generate and use formate. Using vitamin B12 as a cofactor, folic acid can normalize high homocysteine levels by remethylation of homocysteine to methionine via methionine synthetase.

Dosage

Iron Hydroxide Polymaltose + Folic acid + Zinc Sulfate Monohydrate dosage

One tablet daily or two tablets may be required a day in severe cases or as directed by the physician.

May be taken with or without food.

Side Effects

GI disturbances, hypersensitivity reactions; bronchospasm.

Toxicity

IPR-MUS LD50 85 mg/kg,IVN-GPG LD50 120 mg/kg, IVN-MUS LD50 239 mg/kg, IVN-RAT LD50 500 mg/kg, IVN-RBT LD50 410 mg/kg

Precaution

Treatment resistance may occur in patients with depressed haematopoiesis, alcoholism, deficiencies of other vitamins. Neonates.

Interaction

Antiepileptics, oral contraceptives, anti-TB drugs, alcohol, aminopterin, methotrexate, pyrimethamine, trimethoprim and sulphonamides may result to decrease in serum folate contrations. Decreases serum phenytoin concentrations.

Volume of Distribution

Tetrahydrofolic acid derivatives are distributed to all body tissues but are stored primarily in the liver.

Elimination Route

Folic acid is absorbed rapidly from the small intestine, primarily from the proximal portion. Naturally occurring conjugated folates are reduced enzymatically to folic acid in the gastrointestinal tract prior to absorption. Folic acid appears in the plasma approximately 15 to 30 minutes after an oral dose; peak levels are generally reached within 1 hour.

Elimination Route

After a single oral dose of 100 mcg of folic acid in a limited number of normal adults, only a trace amount of the drug appeared in the urine. An oral dose of 5 mg in 1 study and a dose of 40 mcg/kg of body weight in another study resulted in approximately 50% of the dose appearing in the urine. After a single oral dose of 15 mg, up to 90% of the dose was recovered in the urine. A majority of the metabolic products appeared in the urine after 6 hours; excretion was generally complete within 24 hours. Small amounts of orally administered folic acid have also been recovered in the feces. Folic acid is also excreted in the milk of lactating mothers.

Pregnancy & Breastfeeding use

Pregnancy Category A. Adequate and well-controlled human studies have failed to demonstrate a risk to the fetus in the first trimester of pregnancy (and there is no evidence of risk in later trimesters).

Contraindication

Undiagnosed megaloblastic anaemia; pernicious, aplastic or normocytic anaemias.

Storage Condition

Keep below 30°C temperature, away from light & moisture. Keep out of the reach of children.

Innovators Monograph

You find simplified version here Iron Hydroxide Polymaltose + Folic acid + Zinc Sulfate Monohydrate


*** Taking medicines without doctor's advice can cause long-term problems.
Share